Ramu N - Search Results

1

Expect the unexpected: peritoneal spread--late relapse presentation of breast cancer.

Katz D, Peretz T, Maly B, Ospovat I, Salim N, Ramu N, Hovav N, Uziely B. Katz D, et al. Among authors: ramu n. Isr Med Assoc J. 2008 Apr;10(4):310-1. Isr Med Assoc J. 2008. PMID: 18548989 Free article. No abstract available.

2

The diagnostic and prognostic value of ProGRP in lung cancer.

Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. Nisman B, et al. Among authors: ramu n. Anticancer Res. 2009 Nov;29(11):4827-32. Anticancer Res. 2009. PMID: 20032442 Free article.

3

Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.

Nisman B, Biran H, Heching N, Barak V, Ramu N, Nemirovsky I, Peretz T. Nisman B, et al. Among authors: ramu n. Br J Cancer. 2008 Jan 15;98(1):77-9. doi: 10.1038/sj.bjc.6604157. Epub 2007 Dec 18. Br J Cancer. 2008. PMID: 18087272 Free PMC article.

4

Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.

Ramu N, Ramu A, Cole DE, Balis FM, Poplack DG, Pollard HB. Ramu N, et al. Among authors: ramu a. Isr J Med Sci. 1988 Sep-Oct;24(9-10):477-82. Isr J Med Sci. 1988. PMID: 2974448

5

Percutaneous image-guided needle biopsy in children--summary of our experience with 57 children.

Sklair-Levy M, Lebensart PD, Applbaum YH, Ramu N, Freeman A, Gozal D, Gross E, Sherman Y, Bar-Ziv J, Libson E. Sklair-Levy M, et al. Among authors: ramu n. Pediatr Radiol. 2001 Oct;31(10):732-6. doi: 10.1007/s002470100533. Pediatr Radiol. 2001. PMID: 11685444

6

Microsatellite instability and p53 mutations in pediatric secondary malignant neoplasms.

Gafanovich A, Ramu N, Krichevsky S, Pe'er J, Amir G, Ben-Yehuda D. Gafanovich A, et al. Among authors: ramu n. Cancer. 1999 Jan 15;85(2):504-10. Cancer. 1999. PMID: 10023722

7

Reduced ouabain-sensitive potassium entry as a possible mechanism of multidrug-resistance in P388 cells.

Ramu A, Ramu N, Gorodetsky R. Ramu A, et al. Among authors: ramu n. Biochem Pharmacol. 1991 Oct 9;42(9):1699-704. doi: 10.1016/0006-2952(91)90504-x. Biochem Pharmacol. 1991. PMID: 1930295

8

Circumvention of multidrug-resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine.

Ramu A, Ramu N, Rosario LM. Ramu A, et al. Among authors: ramu n. Biochem Pharmacol. 1991 May 15;41(10):1455-61. doi: 10.1016/0006-2952(91)90561-i. Biochem Pharmacol. 1991. PMID: 2018553

9

The cytotoxicity of T-2 toxin and related 12,13-epoxytrichothecenes to Adriamycin-sensitive and -resistant P388 leukemia cells.

Ramu A, Yagen B, Ramu N. Ramu A, et al. Among authors: ramu n. Cancer Chemother Pharmacol. 1989;24(4):264-7. doi: 10.1007/BF00257631. Cancer Chemother Pharmacol. 1989. PMID: 2752509

10

Circumvention of adriamycin resistance by dipyridamole analogues: a structure-activity relationship study.

Ramu N, Ramu A. Ramu N, et al. Among authors: ramu a. Int J Cancer. 1989 Mar 15;43(3):487-91. doi: 10.1002/ijc.2910430324. Int J Cancer. 1989. PMID: 2925278

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters